XFOR
X4 Pharmaceuticals Inc

3,603
Mkt Cap
$329.64M
Volume
548,612.00
52W High
$24.43
52W Low
$1.35
PE Ratio
-0.36
XFOR Fundamentals
Price
$3.62
Prev Close
$3.77
Open
$3.77
50D MA
$3.79
Beta
1.52
Avg. Volume
895,947.77
EPS (Annual)
-$5.59
P/B
1.48
Rev/Employee
$17,881.12
Loading...
Loading...
News
all
press releases
All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy
X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·3d ago
News Placeholder
More News
News Placeholder
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Hold" by Analysts
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) has been assigned a consensus rating of "Hold" from the five ratings firms that are currently covering the company, Marketbeat reports. One...
MarketBeat·10d ago
News Placeholder
Short Interest in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Grows By 27.1%
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling...
MarketBeat·16d ago
News Placeholder
Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Zacks·23d ago
News Placeholder
X4 Pharmaceuticals, Inc. $XFOR Shares Sold by Acorn Capital Advisors LLC
Acorn Capital Advisors LLC lowered its stake in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) by 97.9% in the second quarter, according to the company in its most recent filing with...
MarketBeat·1mo ago
News Placeholder
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Consensus Recommendation of "Hold" from Brokerages
Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) have been given an average rating of "Hold" by the five ratings firms that are presently covering the stock, Marketbeat.com reports...
MarketBeat·1mo ago
News Placeholder
X4 Pharmaceuticals (NASDAQ:XFOR) Stock Rating Lowered by Zacks Research
Zacks Research lowered shares of X4 Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Wednesday...
MarketBeat·2mo ago
News Placeholder
Wall Street Zen Upgrades X4 Pharmaceuticals (NASDAQ:XFOR) to "Hold"
Wall Street Zen raised shares of X4 Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·2mo ago
News Placeholder
MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
MeiraGTx (MGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
News Placeholder
X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +12.66% and -7.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
<
1
2
...
>

Latest XFOR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.